In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis [1]

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1580-1581

  Karlowsky, James A ^a   Laing, Nancy M ^b   Baudry, Trish ^b   Kaplan, Nachum ^c   Vaughan, David ^c   Hoban, Daryl J ^d   Zhanel, George G ^b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Affinium Pharmaceuticals Inc   (Canada)

^d Diagnostic Services of Manitoba Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

API 1252; CIPROFLOXACIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ENZYME INHIBITOR; GENTAMICIN; OXACILLIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CULTURE MEDIUM; DILUTION; DRUG STRUCTURE; GENOTYPE; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS EPIDERMIDIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STRUCTURE ANALYSIS;

ANTI-BACTERIAL AGENTS; BENZOFURANS; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; HUMANS; PYRONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 34247173066     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01254-06     Document Type: Letter

References (9)

1. Campbell, J. W., and J. E. Cronan, Jr. 2001. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 55:305-332.
2. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI M100-S15, vol. 25, no. 1. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Heath, R. J., S. W. White, and C. O. Rock. 2002. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58:695-703.
4. Mulvey, M. R., L. Chiu, J. Ismail, L. Louie, C. Murphy, N. Chang, M. Alfa, and the Canadian Committee for the Standardization of Molecular Methods. 2001. Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis. J. Clin. Microbiol. 39:3481-3485.
5. Mulvey, M. R., L. MacDougall, B. Cholin, G. Horsman, M. Fidyk, and S. Woods. 2005. Community-associated methicillin-resistant Staphylococcus aureus, Canada. Emerg. Infect. Dis. 11:844-850.
6. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A6, 6th ed., vol. 23, no. 2. National Committee for Clinical Laboratory Standards, Wayne, PA.
7. Oliveira, D. C., and H. de Lencastre. 2002. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2155-2161.
8. Payne, D. J., W. H. Miller, V. Berry, J. Brosky, W. J. Burgess, E. Chan, W. E. Wolfe, Jr., A. P. Fosberry, R. Greenwood, M. S. Head, D. A. Heerding, C. A. Janson, D. D. Jaworski, P. M. Keller, P. J. Manley, T. D. Moore, K. A. Newlander, S. Pearson, B. J. Polizzi, X. Qiu, S. F. Rittenhouse, C. Slater-Radosti, K. L. Salyers, M. A. Seefeld, M. G. Smyth, D. T. Takata, I. N. Uzinskas, K. Vaidya, N. G. Wallis, S. B. Winram, C. C. K. Yuan, and W. F. Huffman. 2002. Discovery of a novel and potent class of FabI-directed anti-bacterial agents. Antimicrob. Agents Chemother. 46:3118-3124.
9. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA retriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.